Drug Prices

Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?

Avalere analysis finds Part D prescription drug plans continue to increase patient copays for generics by moving them to higher tiers  

WASHINGTON (April 17, 2024) — The Association for Accessible Medicines, the leading trade association for generic and biosimilar manufacturers, commented on an analysis released yesterday by Avalere showing that Medicare plans increase patient costs for generic medicines by moving thos

AAM Requests Federal Injunction to Block Minnesota’s Unconstitutional Drug Price Law

Generic Pharmaceutical Trade Group Steps in to Protect Patient Access to Affordable Generic Drugs

WASHINGTON, DC (JULY 5, 2023) – The Association for Accessible Medicines (AAM), the trade association representing America’s manufacturers of generic and biosimilar medicines, today filed a lawsuit against Minnesota Attorney General Keith Ellison, requesting that the federal district court in Minnesota enjoin the Attorney General from enforcing the price-control provisions of Senate File 2744. 

A Look Back at Access! 2023

Each year, we look forward to hosting our members, friends, colleagues and partners for Access!, AAM’s annual meeting. Held in Orlando, Florida, this year’s conference was unique in that we also hosted the 25th Annual Meeting of the International Generic and Biosimilar Medicines Association (IGBA) in the same location, a dual experience that helped to strengthen global cooperation in our shared effort to expand patient access to more affordable generic and biosimilar medicines.

A Fireside Chat with AAM Chair, Christine Baeder and Mark Cuban, Entrepreneur and Cost Plus founder.

Entrepreneur and founder of the Mark Cuban Cost Plus Drug Company, PBC, Mark Cuban, sat down with our new Board Chair Christine Baeder, SVP, COO for US Generics at Teva Pharmaceuticals, to discuss his efforts to reduce #drugprices and increase competition in the drug market. #Access2023 #drugprices #patientaccess

AAM Applauds CMS for Requiring Health Plans to Place Generic Drugs On Generic Tiers

WASHINGTON, DC (January 30, 2023) — The Association for Accessible Medicines (AAM) applauds the Centers for Medicare & Medicaid Services (CMS) for several of the recommended provisions outlined in the proposed Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024. In particular, AAM publicly commends the administration’s efforts to standardize plan choice by requiring generic drugs be placed on “generic” tiers and brand-name drugs on “brand-name” tiers. 

Desi is Back Playing Soccer and Doing "Normal Kid" Stuff

When Desi's swollen ankle began hurting so much that he was unable to run and keep up with his friends, his parents, Jonathan and Susan of Maryland, became concerned. After several doctor visits, a rheumatologist diagnosed Desi with juvenile idiopathic arthritis (JIA), an autoimmune disease. To help manage the symptoms of JIA, Desi receives weekly injections of autoimmune suppressant medicine and daily doses of anti-inflammatory medicines.

Generics and Biosimilars Offer Savings for Patients Fighting Cancer, Heart Disease and Other Conditions

Generic and biosimilar medicines improve access and affordability for the millions of people with illnesses like asthma, arthritis, heart disease, and depression. While we now have effective treatment options to help patients manage their conditions, many brand drugs come with steep price tags. Fortunately, there are more affordable generic and biosimilar treatments that reduce costs for patients and increase access to lifesaving care.

Subscribe to Drug Prices

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.